Monash Ivf (ASX:MVF) — Material Events
ASX:MVF · 11 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
Monash IVF Navigates FY25 Profit Dip Amid Market Challenges and Embryo Transfer IncidentsHigh
Monash IVF FY25 profit down 8.1%, faces market softness and embryo transfer incidents; FY26 guidance lowered
22 Aug 2025
·Preliminary Final Report
·85
Monash IVF Navigates FY25 Growth Amid Challenges and Leadership ShiftMedium
Monash IVF reports FY25 revenue and EBITDA growth; no final dividend due to challenges; new CEO appointed for 2026
20 Nov 2025
·Annual General Meeting Address
·80
Monash IVF Firmly Rejects $0.80 Per Share Takeover Bid from Genesis ConsortiumHigh
Monash IVF rejects $0.80 per share acquisition proposal from Genesis Capital consortium
24 Nov 2025
·Takeover Proposal Response
·Unexpected
·80
Monash IVF Posts 5.6% EBITDA Growth Amid Industry HeadwindsMedium
Monash IVF FY25 EBITDA up 5.6%, NPAT in line with guidance; FY26 NPAT guidance $20-23m with focus on market recovery
22 Aug 2025
·Results Presentation
·75
Monash IVF Consortium Raises Offer to $0.90 Per Share with Stringent ConditionsMedium
Monash IVF receives revised $0.90 per share acquisition proposal from Genesis Capital and WHSP Holdings consortium
13 Apr 2026
·Acquisition Proposal
·75
Monash IVF Board Rejects $0.90 Per Share Takeover Offer as UndervaluedMedium
Monash IVF rejects $0.90 per share acquisition proposal from Genesis Capital consortium
20 Apr 2026
·Acquisition Proposal Response
·75
Monash IVF Navigates FY25 Growth Amid Clinical Challenges and Leadership ShiftMedium
Monash IVF posts FY25 underlying NPAT of $27.4m, maintains guidance, plans CEO search and infrastructure expansion
22 Aug 2025
·Full Year Results
·75
Monash IVF Posts Revenue Growth Amid NPAT Dip, Eyes Innovation and Cost ControlMedium
Monash IVF reports FY25 revenue growth, NPAT decline in line with guidance, and outlines cautious FY26 outlook with strategic focus on innovation and cost control
20 Nov 2025
·Annual General Meeting Presentation
·70
Monash IVF Taps Veteran Dr Victoria Atkinson as CEO from May 2026Medium
Monash IVF names Dr Victoria Atkinson as new CEO starting May 2026
11 Nov 2025
·Executive Appointment
·70
Monash IVF Cuts FY26 Profit Forecast as Australian Market Softens but Gains ShareMedium
Monash IVF lowers FY26 earnings guidance amid weaker Australian ART market but gains market share
12 June 2026
·Market and Trading Update
·Unexpected
·70
No articles in this tier for the last 12 months.
Market Mentions
3
- appeared in market wrap coverage
These are market wrap articles where Monash Ivf (ASX:MVF) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 24 (8 June -> 12 June) 2026
13 June 2026
Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026
25 Apr 2026
Healthcare Wrap - Week 16 (13 Apr -> 17 Apr) 2026
18 Apr 2026